CHICAGO–( SERVICE CORD)– Tempus AI, Inc. (NASDAQ: TEM), an innovation firm leading the fostering of AI to progress accuracy medication, today revealed the procurement of Paige, an AI firm concentrating on electronic pathology. The procurement enables Tempus to expand its dataset, increase its seasoned technological group, and develop a solid impact in electronic pathology with a market leading modern technology profile. Established in 2017, Paige has actually created and released a number of AI applications, includ
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/tempus-announces-the-acquisition-of-paige/
